Lidocaine chemical structure
Find information on thousands of medical conditions and prescription drugs.

Lidocaine

Lidocaine (INN) or lignocaine (former BAN) is a popular local anesthetic that is often used in dentistry or topically. The most commonly encountered lidocaine preparations are marketed by AstraZeneca under the brand names Xylocaine and Xylocard, though lidocaine is also found in many other proprietary preparations. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
Labetalol
Lacrisert
Lactitol
Lactuca virosa
Lactulose
Lamictal
Lamisil
Lamivudine
Lamotrigine
Lanophyllin
Lansoprazole
Lantus
Lariam
Larotid
Lasix
Latanoprost
Lescol
Letrozole
Leucine
Leucovorin
Leukeran
Levaquin
Levetiracetam
Levitra
Levocabastine
Levocetirizine
Levodopa
Levofloxacin
Levomenol
Levomepromazine
Levonorgestrel
Levonorgestrel
Levophed
Levora
Levothyroxine sodium
Levoxyl
Levulan
Lexapro
Lexiva
Librium
Lidocaine
Lidopen
Linezolid
Liothyronine
Liothyronine Sodium
Lipidil
Lipitor
Lisinopril
Lithane
Lithobid
Lithonate
Lithostat
Lithotabs
Livostin
Lodine
Loestrin
Lomotil
Loperamide
Lopressor
Loracarbef
Loratadine
Loratadine
Lorazepam
Lortab
Losartan
Lotensin
Lotrel
Lotronex
Lotusate
Lovastatin
Lovenox
Loxapine
LSD
Ludiomil
Lufenuron
Lupron
Lutropin alfa
Luvox
Luxiq
Theophylline
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Its name was coined after the local anesthetic procaine, which in turn replaced cocaine as an anesthetic in dental practice.

History

Lidocaine, the first amide-type local anesthetic, was developed by Nils Löfgren and Bengt Lundqvist in 1943 and first marketed in 1948.

Also used in pet medications.

Pharmacology

Lidocaine is metabolized in the liver to pharmacologically active breakdown products which are excreted by the kidneys. It is faster acting and longer lasting than procaine (Novocain).

When given intravenously, lidocaine is a class Ib antiarrhythmic agent and will block the sodium channel of the cardiac action potential, which decreases automaticity by reducing the slope of phase 4 depolarization with little effect on the PR interval, QRS complex or QT interval.

This drug is used in the treatment of ventricular cardiac arrhythmias and cardiac arrest with ventricular fibrillation, especially with acute ischemia, though it is not useful in the treatment of atrial arrhythmias.

The elimination half life of intravenous lidocaine is about 109 minutes, but because it is metabolized in the liver (which depends on liver blood flow), dosage should be reduced in patients with low cardiac output or who are in shock. In patients with cardiogenic shock, the half life may exceed ten hours.

Toxicity

Toxicity is most often seen when there has been an inadvertent intravascular injection of lidocaine when being used as a local anesthetic. Central nervous system toxicity manifests as tinnitus, dizziness, paresthesia (pins and needles), confusion and – in more severe cases – seizures or coma. Severe toxicity may also result in cardiovascular system collapse or ventricular fibrillation.

Related Information

  • Benzocaine
  • Bupivacaine
  • Procaine
  • Cocaine


Read more at Wikipedia.org


[List your site here Free!]


Nebulized lidocaine and nasogastric tube insertion
From American Family Physician, 5/1/05 by Richard Sadovsky

Insertion of a nasogastric tube can be highly painful for the patient. Small studies have demonstrated that topical anesthesia, including the use of nebulized lidocaine, provides pain relief without significant drug absorption. The addition of nose breathing while the nebulized anesthetic is delivered through the mouth decreases lung deposition of the nebulized solution.

Cullen and associates compared the use of nebulized lidocaine with nose and mouth breathing or nebulized saline before nasogastric tube insertion to reduce procedure discomfort. Fifty adults treated in two emergency departments who required nasogastric tube insertion and did not have pre-existing impairment to gag reflex or a history of reactive airway disease were randomly pre-treated with nebulized lidocaine (400 mg, 4 mL of 10 percent solution)or normal saline (4 mL) in a double-blind manner.

The solution was administered using a face mask and a compressed gas-powered jet nebulizer with an oxygen f low rate of 6 L per minute. The nasogastric tube was inserted immediately after completion of the treatment, using lubricating jelly. Patient discomfort was measured with a visual analog scale. The insertion nurse indicated the difficulty of the insertion using a Likert scale. Complications were recorded.

The visual analog discomfort scale revealed significantly less pain in the lidocaine group than in the placebo group, with no difference in perceived insertion difficulty score noted by the nurses. Epistaxis occurred in five of the 29 patients who received lidocaine and in none of the 21 who received normal saline.

The authors conclude that the use of nebulized lidocaine effectively reduces discomfort associated with nasogastric tube placement (see accompanying table). An increased likelihood of epistaxis, probably caused by injury to insensate turbinate and nasal mucosa, is possible wit h topical anesthesia.

RICHARD SADOVSKY, M.D.

Cullen L, et al. Nebulized lidocaine decreases the discomfort of nasogastric tube insertion: a randomized, double-blind trial. Ann Emerg Med August 2004:44:131-7.

EDITOR 'S NOTE: In an editorial in the same journal, Gallagher 1 reviews the evidence supporting the use of topical anesthesia before nasogastric tube insertion, including (1) lidocaine nasal spray; (2) lidocaine intranasal jelly combined with a tetracaine-plus-benzocaine pharyngeal spray and a nasal vasoconstrictor; (3) nebulized lidocaine added to intransal lidocaine jelly with or without a nasal vaso-constrictor; and (4) the current report on the efficacy of nebulized lidocaine delivered to the nose and the pharynx. Data indicate that patients should no longer have to suffer nasogastric tube insertion without topical anesthesia. Single-use, disposable atomizers are probably the best way to reduce possible cross-contamination. Nebulizers may have a small advantage over atomized spray delivery systems. There has been no evidence of increased inadvertent tracheal intubation secondary to local anesthesia use.--R.S.

Evidence-Based Options for Topical Anesthesia Before Nasogastric Tube Insertion *

Preservative-free lidocaine,10%,4 mL, nebulized by face mask (400 mg of lidocaine total) ([dagger])

Preservative-free lidocaine spray, 4%, delivered by single-dose atomizer to the nose (1.5 mL) and pharynx (3 mL), followed by intranasal lidocaine jelly, 2%, 5 mL, sniffed and swallowed (280 mg of lidocaine total)

*--Two sprays of phenylephrine, 0.5%,in each nostril may decrease the incidence of nosebleeds.

([dagger])--Do not use in patients with asthma.

REFERENCE

(1.) Gallagher EJ. Nasogastric tubes: hard to swallow. Ann Emerg Med 2004:44:138-41.

COPYRIGHT 2005 American Academy of Family Physicians
COPYRIGHT 2005 Gale Group

Return to Lidocaine
Home Contact Resources Exchange Links ebay